UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema

The European respiratory journal, 2011-07, Vol.38 (1), p.176-183

2011

Volltextzugriff (PDF)

Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Annals of oncology, 2024-11, Vol.35 (11), p.993-1002

2024

Volltextzugriff (PDF)

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Annals of oncology, 2023-10, Vol.34 (10), p.899-906

2023

Volltextzugriff (PDF)

Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

ESMO open, 2024-06, Vol.9 (6), p.103465, Article 103465

2024

Volltextzugriff (PDF)

Phase 3 biomarker study for HCC surveillance using AFP, AFP L-3 and DCP. A prospective collection with retrospective blinded evaluation

Journal of hepatology, 2017, Vol.66 (1), p.S222-S223

2017

Volltextzugriff (PDF)

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status

ESMO open, 2024-11, Vol.9 (11), p.103973, Article 103973

2024

Volltextzugriff (PDF)

394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)

Annals of oncology, 2024-09, Vol.35, p.S384-S385

2024

Volltextzugriff (PDF)

246P Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial

Annals of oncology, 2024-09, Vol.35, p.S318-S318

2024

Volltextzugriff (PDF)

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

Annals of oncology, 2023-10, Vol.34, p.S298-S298

2023

Volltextzugriff (PDF)

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Annals of oncology, 2022-05, Vol.33, p.S124-S124

2022

Volltextzugriff (PDF)

Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events

Biostatistics (Oxford, England), 2015-01, Vol.16 (1), p.73-83

2015

Volltextzugriff (PDF)

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

Gynecologic oncology, 2020-10, Vol.159, p.5-5

2020

Volltextzugriff (PDF)

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

Annals of oncology, 2020-09, Vol.31, p.S1165-S1165

2020

Volltextzugriff (PDF)

THU-105 - Phase 3 biomarker study for HCC surveillance using AFP, AFP L-3 and DCP. A prospective collection with retrospective blinded evaluation

Journal of hepatology, 2017, Vol.66 (1), p.S222-S223

2017

Volltextzugriff (PDF)

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer

International journal of radiation oncology, biology, physics, 2021-11, Vol.111 (3), p.S34-S34

2021

Volltextzugriff (PDF)

213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC)

ESMO open, 2024-05, Vol.9, p.103235, Article 103235

2024

Volltextzugriff (PDF)

6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials

ESMO open, 2023-05, Vol.8 (1), p.101230, Article 101230

2023

Volltextzugriff (PDF)

B22 THAT'LL BE THE DAY: UNDERSTANDING IPF RISK FACTORS AND OUTCOMES: Ability Of Gender-Age-Physiology Index Stage To Predict Future Rate Of Pulmonary Function Decline In Idiopathic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

A41 INTERSTITIAL LUNG DISEASE: RISK FACTORS AND OUTCOMES: The Role Of High Resolution CT Patterns In Prognosticating Ipf

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Volltextzugriff (PDF)

Neuraxial Anaesthesia in a Patient with Charcot-Marie-Tooth Disease and Hip Fracture- A Case Report and Literature Review

Middle East Journal of Medical Case Reports, 2024-06, Vol.4 (3), p.23-26

2024

Volltextzugriff (PDF)

C37 COPD: WHAT IS NEW IN IMAGING?: CT Emphysema Score (emphysema, Age, Smoking, Size - Emphasize) Identifies Clinically Significant COPD

American journal of respiratory and critical care medicine, 2014-01, Vol.189, p.1

2014

Volltextzugriff (PDF)

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study

The lancet respiratory medicine, 2014-07, Vol.2 (7), p.548-556

2014

Volltextzugriff (PDF)

TP53-associated early breast cancer: new observations from a large cohort

JNCI : Journal of the National Cancer Institute, 2024-08, Vol.116 (8), p.1246-1254

2024

Volltextzugriff (PDF)

DETECT: Development of Technologies for Early HCC Detection

Gastroenterology (New York, N.Y. 1943), 2022-07, Vol.163 (1), p.21-27

2022

Volltextzugriff (PDF)

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer

Breast cancer research and treatment, 2024-02, Vol.204 (1), p.123-132

2024

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(36)
Berichte
(1)

Sprache

Englisch
(37)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Humans
(10)
Life Sciences & Biomedicine
(10)
Female
(7)
Aged
(5)
Middle Aged
(5)
Adult
(4)
Breast Cancer
(3)
Breast Neoplasms - Pathology
(3)
Male
(3)
Oncology
(3)
Survival
(3)
Biological And Medical Sciences
(2)
Chronic Obstructive Pulmonary Disease
(2)
General & Internal Medicine
(2)
Internal Medicine
(2)
Medical Sciences
(2)
Medicine
(2)
Metastatic Breast Cancer
(2)
Recurrence
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema

Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022

Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer

Phase 3 biomarker study for HCC surveillance using AFP, AFP L-3 and DCP. A prospective collection with retrospective blinded evaluation

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status

394P Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)

246P Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial

285P Treatment patterns and clinical outcomes of germline BRCA mutation (gBRCAm)-associated breast cancer (BC): A matched, case-control study

1MO Prognostic and biologic significance of HER2-low expression in early breast cancer

Nonparametric tests of treatment effect based on combined endpoints for mortality and recurrent events

A phase II trial of the Wee1 inhibitor adavosertib (AZD1775) in recurrent uterine serous carcinoma

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

THU-105 - Phase 3 biomarker study for HCC surveillance using AFP, AFP L-3 and DCP. A prospective collection with retrospective blinded evaluation

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer

213P Sequencing antibody-drug conjugates (ADCs) in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (mBC)

6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials

B22 THAT'LL BE THE DAY: UNDERSTANDING IPF RISK FACTORS AND OUTCOMES: Ability Of Gender-Age-Physiology Index Stage To Predict Future Rate Of Pulmonary Function Decline In Idiopathic Pulmonary Fibrosis

A41 INTERSTITIAL LUNG DISEASE: RISK FACTORS AND OUTCOMES: The Role Of High Resolution CT Patterns In Prognosticating Ipf

Neuraxial Anaesthesia in a Patient with Charcot-Marie-Tooth Disease and Hip Fracture- A Case Report and Literature Review

C37 COPD: WHAT IS NEW IN IMAGING?: CT Emphysema Score (emphysema, Age, Smoking, Size - Emphasize) Identifies Clinically Significant COPD

Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study

TP53-associated early breast cancer: new observations from a large cohort

DETECT: Development of Technologies for Early HCC Detection

A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer

Suchergebnisse filtern